Comparison of survival outcomes according of patients with metastatic gastric cancer receiving trastuzumab with systemic chemotherapy.
Drug therapy
Esophagogastric junction
Stomach
Survival
Trastuzumab
Journal
Korean journal of clinical oncology
ISSN: 2288-4084
Titre abrégé: Korean J Clin Oncol
Pays: Korea (South)
ID NLM: 9918521386106676
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
09
09
2020
revised:
11
11
2020
accepted:
18
11
2020
entrez:
22
3
2023
pubmed:
1
12
2020
medline:
1
12
2020
Statut:
ppublish
Résumé
Currently, trastuzumab plus chemotherapy is the standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic gastric cancer (mGC) or esophagogastric junction cancer. However, it is not clear whether the prognosis of HER2-positive mGC treated with trastuzumab plus chemotherapy is better than that of HER2-negative mGC treated with chemotherapy as the first-line therapy. We performed a retrospective study comparing the prognosis of mGC according to first-line treatment with trastuzumab plus chemotherapy or chemotherapy only, at the Korea Cancer Center Hospital from 2011 to 2018. The Kaplan-Meier method and Cox proportional hazards model were used for univariate and multivariate survival analyses. The median overall survival of trastuzumab group was 26.1 months and that of chemotherapy group was 14.8 months (P=0.047). Trastuzumab group had a longer median progression-free survival than chemotherapy group (23.4 vs. 9.2 months, P=0.026). By univariate analysis, sex, age, World Health Organization (WHO) histology, HER2 status, primary tumor site, extent of disease, number of lesions, number of metastatic, measurability of disease, prior gastrectomy, and chemotherapy group are statistically significant. Using multivariate analysis, number of lesions, number of metastatic, prior gastrectomy, and trastuzumab group (hazard ratio, 0.594; 95% confidence interval, 0.384-0.921; P=0.020) were found to be independent prognostic factors of overall survival. The result suggests prognosis of HER2-positive mGC treated by trastuzumab plus chemotherapy could be better than that of HER2-negative mGC treated by chemotherapy only. Well-designed prospective cohort studies are needed to confirm the results of this study. HER2 testing should be performed routinely in all patients newly diagnosed with mGC.
Identifiants
pubmed: 36945715
doi: 10.14216/kjco.20011
pii: kjco-16-2-63
pmc: PMC9942733
doi:
Types de publication
Journal Article
Langues
eng
Pagination
63-70Informations de copyright
Copyright © 2020 Korean Society of Surgical Oncology.
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.
Références
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Clin Oncol. 2006 Jun 20;24(18):2903-9
pubmed: 16782930
Clin Cancer Res. 2009 Dec 15;15(24):7479-7491
pubmed: 20008848
Oncogene. 2003 Sep 29;22(42):6570-8
pubmed: 14528282
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Ann Oncol. 2005 Feb;16(2):273-8
pubmed: 15668283
Ann Oncol. 2001;12 Suppl 1:S3-8
pubmed: 11521719
J Cancer. 2012;3:137-44
pubmed: 22481979
J Clin Oncol. 2000 Jun;18(11):2201-9
pubmed: 10829039
Int J Cancer. 2014 May 15;134(10):2468-77
pubmed: 24155030
J Clin Pathol. 2012 Aug;65(8):751-7
pubmed: 22569536
Cancer. 1999 May 1;85(9):1894-902
pubmed: 10223227
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Br J Cancer. 2006 Jan 30;94(2):259-67
pubmed: 16404427
Cancer Res Treat. 2018 Apr;50(2):303-316
pubmed: 29566481
Ann Surg Oncol. 2011 Oct;18(10):2833-40
pubmed: 21468783
Clin Cancer Res. 2005 Jul 1;11(13):4898-904
pubmed: 16000588
Ann Oncol. 2012 Oct;23(10):2656-2662
pubmed: 22689179
J Gastric Cancer. 2019 Mar;19(1):1-48
pubmed: 30944757
J Natl Compr Canc Netw. 2016 Oct;14(10):1286-1312
pubmed: 27697982
Ann Oncol. 2001;12 Suppl 1:S9-13
pubmed: 11521729
J Clin Oncol. 2011 Aug 1;29(22):3030-6
pubmed: 21709195
World J Gastroenterol. 2012 May 21;18(19):2402-7
pubmed: 22654433
Anticancer Res. 2012 Apr;32(4):1547-53
pubmed: 22493400
Gastric Cancer. 2013 Apr;16(2):261-7
pubmed: 22797858
Cancers (Basel). 2018 Sep 20;10(10):
pubmed: 30241301
Dig Dis Sci. 2006 Aug;51(8):1371-9
pubmed: 16868827